The cost effectiveness of treating paediatric cancer in low-income and middle-income countries: a case-study approach using acute lymphocytic leukaemia in Brazil and Burkitt lymphoma in Malawi
- 30 November 2012
- journal article
- research article
- Published by BMJ in Archives of Disease in Childhood
- Vol. 98 (2), 155-160
- https://doi.org/10.1136/archdischild-2011-301419
Abstract
Approximately 90% of children with cancer reside in low-income and middle-income countries (LMIC) where healthcare resources are scarce and allocation decisions difficult. The cost effectiveness of treating childhood cancers in these settings is unknown. The objective of the present work was to determine cost-effectiveness thresholds for common paediatric cancers using acute lymphoblastic leukaemia (ALL) in Brazil and Burkitt lymphoma (BL) in Malawi as examples. Disability-adjusted life years (DALYs) prevented by treatment were compared to the gross domestic product (GDP) per capita of each country to define cost-effectiveness thresholds using WHO-CHOICE (‘CHOosing Interventions that are Cost-Effective’) guidelines. The case examples were selected due to the data available and because ALL and BL both have the potential to yield significant health gains at a low cost per patient treated. The key findings were as follows: the 3:1 cost/DALY prevented to GDP/capita ratio for ALL in Brazil was US$771 225; expenditures below this threshold were cost effective. Costs below US$257 075 (1:1 ratio) were considered very cost effective. Analogous thresholds for BL in Malawi were US$42 729 and US$14 243. Actual costs were far less. In Brazil, US$16 700 was spent to treat each patient while in Malawi total drug costs were less than US$50 per child. In summary, treatment of certain paediatric cancers in LMIC is very cost effective. Future research should evaluate actual treatment and infrastructure expenditures to help guide policymakers.Keywords
This publication has 19 references indexed in Scilit:
- Burkitt's lymphomaThe Lancet, 2012
- Cost‐effectiveness of treatment of childhood acute lymphoblastic leukemia with chemotherapy only: The influence of new medication and diagnostic technologyPediatric Blood & Cancer, 2011
- Predictors of outcome and methodological issues in children with acute lymphoblastic leukaemia in El SalvadorEuropean Journal Of Cancer, 2010
- Expansion of cancer care and control in countries of low and middle income: a call to actionThe Lancet, 2010
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Screening, prevention and treatment of cervical cancer—A global and regional generalized cost-effectiveness analysisVaccine, 2009
- Long‐term outcome of childhood acute lymphoblastic leukemia treated in ChinaPediatric Blood & Cancer, 2008
- Childhood cancer epidemiology in low‐income countriesCancer, 2007
- Treatment of Wilms tumor according to SIOP 9 protocol in Casablanca, MoroccoPediatric Blood & Cancer, 2005
- Trends in leukemia incidence and survival in the United States (1973–1998)Cancer, 2003